Wuhan Haite Biopharmaceutical Overview
- Year Founded
-
1992
- Status
-
Public
- Employees
-
958
- Stock Symbol
-
300683
- Investments
-
4
- Share Price
-
$2.82
- (As of Friday Closing)
Wuhan Haite Biopharmaceutical General Information
Description
Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical manufacturing enterprise in China. The company is primarily engaged in the development, production and sale of biological products. Its product portfolio comprises rat nerve growth factor freeze-dried powder injection, injection of anti-hepatitis B transfer factor freeze-dried powder injection, thrombin and other chemicals. The company also has more than 20 kinds of products such as hepatitis B treatment drug op Heparin and hemostatic agent thrombin.
Contact Information
Website
www.hiteck.com.cnCorporate Office
- Haite Science and Technology Park, Wuhan Economic Development Zone
- Wuhan, Hubei 430056
- China
Corporate Office
- Haite Science and Technology Park, Wuhan Economic Development Zone
- Wuhan, Hubei 430056
- China
Wuhan Haite Biopharmaceutical Stock Performance
As of 20-Nov-2026, Wuhan Haite Biopharmaceutical’s stock price is $2.82. Its current market cap is $369M with 131M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.82 | $2.98 | $2.82 - $7.37 | $369M | 131M | 5.92M | -$0.21 |
Wuhan Haite Biopharmaceutical Financials Summary
As of 30-Sep-2026, Wuhan Haite Biopharmaceutical has a trailing 12-month revenue of $62.9M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 449,103 | 426,283 | 316,434 | 515,596 |
| Revenue | 62,865 | 75,292 | 90,444 | 85,130 |
| EBITDA | (29,979) | (20,363) | 878 | (12,511) |
| Net Income | (27,920) | (32,159) | (9,665) | (17,078) |
| Total Assets | 360,196 | 368,251 | 402,273 | 419,159 |
| Total Debt | 5,133 | 10,143 | 6,370 | 9,304 |
Wuhan Haite Biopharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Wuhan Haite Biopharmaceutical Signals
Wuhan Haite Biopharmaceutical Investments & Acquisitions (4)
Wuhan Haite Biopharmaceutical’s most recent deal was a Merger/Acquisition with Shadong Biotechnology for . The deal was made on 27-Feb-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Shadong Biotechnology | 27-Feb-2024 | Merger/Acquisition | Biotechnology | ||
| Shadong Biotechnology | 22-Dec-2021 | Secondary Transaction - Private | Biotechnology | ||
| CVI Pharmaceuticals | 21-Jul-2021 | Later Stage VC | Drug Discovery | ||
| Weijia Pharmaceutical | 08-Dec-2020 | Merger/Acquisition | Drug Discovery |
Wuhan Haite Biopharmaceutical ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Wuhan Haite Biopharmaceutical Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Weijia Pharmaceutical | Xiamen, China | 2017 | |
| Shadong Biotechnology | Beijing, China | 2001 |
Wuhan Haite Biopharmaceutical FAQs
-
When was Wuhan Haite Biopharmaceutical founded?
Wuhan Haite Biopharmaceutical was founded in 1992.
-
Where is Wuhan Haite Biopharmaceutical headquartered?
Wuhan Haite Biopharmaceutical is headquartered in Wuhan, China.
-
What is the size of Wuhan Haite Biopharmaceutical?
Wuhan Haite Biopharmaceutical has 958 total employees.
-
What industry is Wuhan Haite Biopharmaceutical in?
Wuhan Haite Biopharmaceutical’s primary industry is Drug Discovery.
-
Is Wuhan Haite Biopharmaceutical a private or public company?
Wuhan Haite Biopharmaceutical is a Public company.
-
What is Wuhan Haite Biopharmaceutical’s stock symbol?
The ticker symbol for Wuhan Haite Biopharmaceutical is 300683.
-
What is the current stock price of Wuhan Haite Biopharmaceutical?
As of 20-Nov-2026 the stock price of Wuhan Haite Biopharmaceutical is $2.82.
-
What is the current market cap of Wuhan Haite Biopharmaceutical?
The current market capitalization of Wuhan Haite Biopharmaceutical is $369M.
-
What is Wuhan Haite Biopharmaceutical’s current revenue?
The trailing twelve month revenue for Wuhan Haite Biopharmaceutical is $62.9M.
-
What is Wuhan Haite Biopharmaceutical’s annual earnings per share (EPS)?
Wuhan Haite Biopharmaceutical’s EPS for 12 months was -$0.21.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process